4-Aminopyridine, a Voltage-Gated K+ Channel Inhibitor, Attenuates Nitric Oxide-Mediated Vasodilation of Retinal Arterioles in Rats. 2020

Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
Department of Molecular Pharmacology, Kitasato University School of Pharmaceutical Sciences.

Nitric oxide (NO) is an important regulator of the retinal blood flow. The present study aimed to determine the role of voltage-gated K+ (KV) channels and ATP-sensitive K+ (KATP) channels in NO-mediated vasodilation of retinal arterioles in rats. In vivo, the retinal vasodilator responses were assessed by measuring changes in the diameter of retinal arterioles from ocular fundus images. Intravitreal injection of 4-aminopyridine (a KV channel inhibitor), but not glibenclamide (a KATP channel blocker), significantly attenuated the retinal vasodilator response to the NO donor (±)-(E)-4-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide (NOR3). Intravitreal injection of indomethacin (a non-selective cyclooxygenase inhibitor) also reduced the NOR3-induced retinal vasodilator response. The combination of 4-aminopyridine and indomethacin produced a greater reduction in the NOR3-induced response than either agent alone. 4-Aminopyridine had no significant effect on pinacidil (a KATP channel opener)-induced response. These results suggest that the vasodilatory effects of NO are mediated, at least in part, through the activation of 4-aminopyridine-sensitive KV channels in the retinal arterioles of rats. NO exerts its dilatory effect on the retinal vasculature of rats through at least two mechanisms, activation of the KV channels and enhancement of prostaglandin production.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D008297 Male Males
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001160 Arterioles The smallest divisions of the arteries located between the muscular arteries and the capillaries. Arteriole
D012171 Retinal Vessels The blood vessels which supply and drain the RETINA. Pecten Oculi,Retinal Vasculature,Retinal Blood Vessels,Retinal Blood Vessel,Retinal Vasculatures,Retinal Vessel,Vasculature, Retinal,Vessel, Retinal,Vessel, Retinal Blood
D014664 Vasodilation The physiological widening of BLOOD VESSELS by relaxing the underlying VASCULAR SMOOTH MUSCLE. Vasodilatation,Vasorelaxation,Vascular Endothelium-Dependent Relaxation,Endothelium-Dependent Relaxation, Vascular,Relaxation, Vascular Endothelium-Dependent,Vascular Endothelium Dependent Relaxation
D015761 4-Aminopyridine One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes. 4-Aminopyridine Sustained Release,Dalfampridine,Fampridine-SR,Pymadine,VMI-103,4 Aminopyridine,4 Aminopyridine Sustained Release,Fampridine SR,Sustained Release, 4-Aminopyridine,VMI 103,VMI103
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats
D026902 Potassium Channel Blockers A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS. Channel Blockers, Potassium,Potassium Channel Blocker,Blocker, Potassium Channel,Blockers, Potassium Channel,Channel Blocker, Potassium

Related Publications

Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
May 2015, Naunyn-Schmiedeberg's archives of pharmacology,
Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
November 2006, Zhonghua fu chan ke za zhi,
Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
April 2003, European journal of pharmacology,
Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
January 2015, PloS one,
Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
April 2013, Experimental eye research,
Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
August 2023, Experimental eye research,
Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
July 2006, American journal of physiology. Heart and circulatory physiology,
Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
December 2005, European journal of pharmacology,
Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
March 2007, Vascular pharmacology,
Asami Mori, and Ryo Namekawa, and Kenji Sakamoto, and Kunio Ishii, and Tsutomu Nakahara
February 2018, British journal of pharmacology,
Copied contents to your clipboard!